Log in

NASDAQ:EVGN - Evogene Stock Price, Forecast & News

-0.09 (-5.97 %)
(As of 12/16/2019 02:28 AM ET)
Today's Range
Now: $1.42
50-Day Range
MA: $1.47
52-Week Range
Now: $1.42
Volume1,653 shs
Average Volume12,830 shs
Market Capitalization$36.47 million
P/E RatioN/A
Dividend YieldN/A
Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics. Read More…

Industry, Sector and Symbol

Industry Agricultural chemicals
Current SymbolNASDAQ:EVGN



Sales & Book Value

Annual Sales$1.75 million
Book Value$1.95 per share


Net Income$-20,760,000.00
Net Margins-1,402.12%


Market Cap$36.47 million
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable

Receive EVGN News and Ratings via Email

Sign-up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter.

Evogene (NASDAQ:EVGN) Frequently Asked Questions

What is Evogene's stock symbol?

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

How were Evogene's earnings last quarter?

Evogene Ltd (NASDAQ:EVGN) released its quarterly earnings data on Tuesday, May, 29th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.02. The biotechnology company earned $0.37 million during the quarter. Evogene had a negative return on equity of 34.62% and a negative net margin of 1,402.12%. View Evogene's Earnings History.

When is Evogene's next earnings date?

Evogene is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Evogene.

Has Evogene been receiving favorable news coverage?

Media coverage about EVGN stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Evogene earned a daily sentiment score of -1.6 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Evogene.

Are investors shorting Evogene?

Evogene saw a decrease in short interest in November. As of November 15th, there was short interest totalling 8,100 shares, a decrease of 8.0% from the October 31st total of 8,800 shares. Based on an average daily volume of 5,700 shares, the short-interest ratio is currently 1.4 days. Currently, 0.0% of the company's shares are sold short. View Evogene's Current Options Chain.

Who are some of Evogene's key competitors?

What other stocks do shareholders of Evogene own?

Who are Evogene's key executives?

Evogene's management team includes the folowing people:
  • Mr. Ofer Haviv, CEO & Pres (Age 53)
  • Ms. Dorit Kreiner, Interim Chief Financial Officer
  • Mr. Mark Kapel, Exec. VP of Technology (Age 42)
  • Dr. Eyal Emmanuel, Chief Scientific Officer (Age 46)
  • Ms. Sigal Fattal, Exec. Officer (Age 48)

Who are Evogene's major shareholders?

Evogene's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Phoenix Holdings Ltd. (1.02%).

Which major investors are buying Evogene stock?

EVGN stock was bought by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd..

How do I buy shares of Evogene?

Shares of EVGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Evogene's stock price today?

One share of EVGN stock can currently be purchased for approximately $1.42.

How big of a company is Evogene?

Evogene has a market capitalization of $36.47 million and generates $1.75 million in revenue each year. View Additional Information About Evogene.

What is Evogene's official website?

The official website for Evogene is http://www.evogene.com/.

How can I contact Evogene?

Evogene's mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 76121. The biotechnology company can be reached via phone at 972-8931-1900 or via email at [email protected]

MarketBeat Community Rating for Evogene (NASDAQ EVGN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  196 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  433
MarketBeat's community ratings are surveys of what our community members think about Evogene and other stocks. Vote "Outperform" if you believe EVGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Featured Article: What is systematic risk?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel